Please login to the form below

Not currently logged in
Email:
Password:

Novartis' Reclast for osteoporosis approved by FDA

Swiss pharmaceutical company Novartis has won FDA approval for its osteoposis drug, Reclast (zoledronic acid), for the treatment of women with postmenopausal osteoporosis.

Swiss pharmaceutical company Novartis has won FDA approval for its osteoposis drug, Reclast (zoledronic acid), for the treatment of women with postmenopausal osteoporosis.

Novartis added that the European Commission (EC) is also expected to give its approval for Reclast in Q4 2007, following the positive opinion of the Committee for Medicinal Products. Reclast is already sold in the US and the EU as a treatment for Paget's disease.

In a clinical study involving more than 7,700 women, Reclast reduced the risk of spine fracture by 70 per cent and hip fracture by 41 per cent, Novartis said in a statement. The drug is administered as a once yearly intravenous injection.

Reclast is already in clinical studies to test Reclast's efficacy in the treatment of male osteoporosis.

According to a Datamonitor report, the osteoporosis market is due for a major upheaval when market leader Fosamax (alendronate) loses its US patent. New market entrants provide further complexity to the competitive landscape but will also drive market growth over the next ten years.

Eli Lilly has launched two osteoporosis drugs, Evista (raloxifene) and Forteo (teriparatide). In 2006, Evista generated sales of USD 739, while Forteo generated revenue of USD 574m.

21st August 2007

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Research Partnership

We are the largest independent healthcare market research and consulting agencies in the world. Trusted partner to the global pharmaceutical...

Latest intelligence

Health literacy in the time of COVID-19
In a time when much of the media’s focus is on the ongoing COVID-19 pandemic and the differences in vaccination rates between various regions, countries, and socioeconomic groups, improving health...
Rare thoughts & outcomes - navigating pathways to better outcomes in rare
...
How to pick the perfect training program for your healthcare professionals
You know your team needs training. But not all training providers and programs are created equal. Last week, we shared the benefits of working with specialist learning and development (L&D)...